

# **C3 Glomerulonephritis Associated with IgM Monoclonal Gammopathy and Low Grade B-Cell Lymphoma**

**Dalya Al-Qaysi, M.D.**

**Yaseen Aleatany M.D.**

**Gahyun Gim, M.D.**

**Tala Eneizat Mahdawi, M.D.**

**Vaidyanathapuram Balakrishnan, M.D.**

St Elizabeth's Medical Center  
Department of Internal Medicine  
Brighton, MA, United States

Tufts University  
School of Medicine  
Boston, MA, United States

# BACKGROUND

## EPIDEMIOLOGY:

- C3 glomerulopathies are rare diseases with an estimated incidence of 1-3 cases/1,000,000 and point prevalence of 14 to 140 cases per 1,000,000. [1]
- The term C3 glomerulopathy was introduced recently to encompass all glomerular lesions with predominant C3 accumulation, which includes dense deposit disease (DDD) and C3 glomerulonephritis (C3GN). [2,3].

## PATHOGENESIS:

- Mainly due to excessive activation or dysregulation of the complement alternate pathway, which is highly organized by the activity of C3 convertase. This dysregulation may occur as a result of mutations or functional inhibition of complement-regulatory proteins.
- The activity of C3 convertase can be increased by:
  - Increased production of C3 nephritic factors (C3NeFs).
  - Loss of functional factor H.
  - Enzymatic cleavage of C3 by renin.




# BACKGROUND

- The exact mechanism is still not well understood. But the disease process was found either inherited or acquired.
- The acquired mechanism is usually related to triggering factors including: **Surgeries, infections, traumas, paraprotein and tumors.**

An association with hematological cancers is largely based on the observation that functional inhibition of complement-regulating proteins may result from a monoclonal gammopathy. [4]




# COMPLEMENT PATHWAY IN GLOMERULONEPHRITIS



- System of circulating proteins that form an important component of innate immunity
- 3 pathways of activation that converge at C3
- Classical pathway activated by immune complexes
- Activation of C3 leads to the formation of the membrane attack complex





Adapted from : Smith RJH, Appel GB, Blom AM, et al. C3 glomerulopathy - understanding a rare complement-driven renal disease. Nat Rev Nephrol 2019; 15:129 [1]

# CASE PRESENTATION

78-year-old man with hypertension, who underwent left total hip arthroplasty, that was complicated by wound infection requiring incision and drainage with a wound culture growth of MRSA and *Proteus mirabilis*. He was appropriately treated then discharged. Readmitted with persistent left hip pain, worsening dependent edema, and profound oligoanuric acute kidney injury with a serum creatinine (S.Cr) of  $>9$  mg/dL.

## Urine studies:

- Proteinuria
- Microscopic hematuria
- Urine sediment showed numerous erythrocytes, leukocytes but no cellular casts.
- Random urine protein:creatinine ratio was  $>2.5$  g/g.





# CASE PRESENTATION



Serological work-up:

- Low C3 and normal C4 level.
- Positive perinuclear anti-neutrophil cytoplasmic antibodies (p-ANCA) with undetectable anti-myeloperoxidase antibodies.
- Serum and urine protein electrophoresis with immunofixation was positive for an IgM-kappa monoclonal paraprotein.





Slide A and B: Renal biopsy tissue electron microscopy shows subendothelial, intramembranous, and hump-like subepithelial and mesangial electron dense deposit.



Slide C and D: Renal biopsy , immunofluorescence (IF) staining microscopy studies shows C) C3 immunofluorescent staining and D) IgM/Kappa restricted cellular infiltrate in the interstitium.

## BONE MARROW BIOPSY

Negative for multiple myeloma or lymphoma but flow cytometry demonstrated a mild clonal excess of B lymphocytes of uncertain significance (kappa:lambda ratio=8) raising the possibility of a **low grade B-cell lymphoma**.



# TREATMENT COURSE

He was initiated on high dose intravenous methylprednisolone followed by high dose oral prednisone. 72-hrs later, his urine output improved and hemodialysis was discontinued. At discharge, his S.Cr was 2.8 mg/dL.

Corticosteroids were slowly tapered during three months and he received four doses of weekly rituximab infusion. Subsequently, proteinuria resolved and S.Cr stabilized.



# CONCLUSION

- C3GN is a rare disease that usually occurs after a triggering event in predisposed/vulnerable patients. A previous study showed that a history of infection, positive autoimmune findings, and monoclonal gammopathy (IgM) were present in 33 of 114 (28.9%), 28 of 114 (24.6%), and 36 of 95 (37.9%) patients, respectively [4].
- In the present study, we present the case of a patient with multiple triggering factors that resulted in C3GN which was responsive to management with glucocorticoids and immunomodulatory therapy.



# REFERENCES

1. Smith RJH, Appel GB, Blom AM, et al. C3 glomerulopathy - understanding a rare complement-driven renal disease. *Nat Rev Nephrol* 2019; 15:129.
2. Fakhouri F, Frémeaux-Bacchi V, Noël LH, et al. C3 glomerulopathy: a new classification. *Nat Rev Nephrol* 2010; 6:494.
3. Bomback AS, Appel GB. Pathogenesis of the C3 glomerulopathies and reclassification of MPGN. *Nat Rev Nephrol* 2012; 8:634.
4. Ravindran A, Fervenza FC, Smith RJH, De Vriese AS, Sethi S., C3 Glomerulopathy: Ten Years' Experience at Mayo Clinic. *Mayo Clin Proc.* 2018 Aug
5. Zand L, Kattah A, Fervenza FC, Sethi S., C3 glomerulonephritis associated with monoclonal gammopathy: a case series. *Am J Kidney Dis.* 2013 Sep.
6. Renal pathology biopsy slides has been provided by Renal Pathology Services - Brigham and Women's Hospital.

